Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura

Chronic immune thrombocytopenic purpura (ITP) is an acquired hematologic condition that involves immune-mediated platelet destruction with resultant bleeding of variable severity. Refractory ITP occurs when patients fail to tolerate and/or respond to multiple treatment modalities. In this case, we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Cochran, Audra L, Schuldt, Meredith M, Quinn, James M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615384/
https://www.ncbi.nlm.nih.gov/pubmed/37908928
http://dx.doi.org/10.7759/cureus.46278
_version_ 1785129210209107968
author Cochran, Audra L
Schuldt, Meredith M
Quinn, James M
author_facet Cochran, Audra L
Schuldt, Meredith M
Quinn, James M
author_sort Cochran, Audra L
collection PubMed
description Chronic immune thrombocytopenic purpura (ITP) is an acquired hematologic condition that involves immune-mediated platelet destruction with resultant bleeding of variable severity. Refractory ITP occurs when patients fail to tolerate and/or respond to multiple treatment modalities. In this case, we examine the clinical course of a 39-year-old female with refractory ITP and discuss how we navigated a multitude of challenges by adapting an established desensitization protocol to meet our patient’s needs. To our knowledge, we describe the first successful desensitization to ofatumumab for use in ITP in the current literature.
format Online
Article
Text
id pubmed-10615384
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-106153842023-10-31 Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura Cochran, Audra L Schuldt, Meredith M Quinn, James M Cureus Internal Medicine Chronic immune thrombocytopenic purpura (ITP) is an acquired hematologic condition that involves immune-mediated platelet destruction with resultant bleeding of variable severity. Refractory ITP occurs when patients fail to tolerate and/or respond to multiple treatment modalities. In this case, we examine the clinical course of a 39-year-old female with refractory ITP and discuss how we navigated a multitude of challenges by adapting an established desensitization protocol to meet our patient’s needs. To our knowledge, we describe the first successful desensitization to ofatumumab for use in ITP in the current literature. Cureus 2023-09-30 /pmc/articles/PMC10615384/ /pubmed/37908928 http://dx.doi.org/10.7759/cureus.46278 Text en Copyright © 2023, Cochran et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Cochran, Audra L
Schuldt, Meredith M
Quinn, James M
Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
title Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
title_full Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
title_fullStr Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
title_full_unstemmed Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
title_short Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
title_sort ofatumumab desensitization protocol: a case of refractory immune thrombocytopenic purpura
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615384/
https://www.ncbi.nlm.nih.gov/pubmed/37908928
http://dx.doi.org/10.7759/cureus.46278
work_keys_str_mv AT cochranaudral ofatumumabdesensitizationprotocolacaseofrefractoryimmunethrombocytopenicpurpura
AT schuldtmeredithm ofatumumabdesensitizationprotocolacaseofrefractoryimmunethrombocytopenicpurpura
AT quinnjamesm ofatumumabdesensitizationprotocolacaseofrefractoryimmunethrombocytopenicpurpura

Ejemplares similares